Testing for heritable thrombophilia in children at Starship Children's Hospital: An audit of requests between 2004 and 2009
Version of Record online: 19 AUG 2012
© 2012 The Authors. Journal of Paediatrics and Child Health © 2012 Paediatrics and Child Health Division (Royal Australasian College of Physicians)
Journal of Paediatrics and Child Health
Volume 48, Issue 10, pages 921–925, October 2012
How to Cite
Bradbeer, P., Teague, L. and Cole, N. (2012), Testing for heritable thrombophilia in children at Starship Children's Hospital: An audit of requests between 2004 and 2009. Journal of Paediatrics and Child Health, 48: 921–925. doi: 10.1111/j.1440-1754.2012.02517.x
- Issue online: 24 OCT 2012
- Version of Record online: 19 AUG 2012
- Accepted for publication 10 November 2011.
- venous thromboembolism
Aims: The aim of this study was to review patterns of requests for heritable thrombophilia and to audit these findings against an international standard.
Methods: Review of requests for antithrombin, protein C, protein S, activated protein C resistance, Factor V Leiden and prothrombin G20210A mutation analysis in children <16 years between 1/1/2004 and 31/12/2009. Data for patient characteristics, test results, origin of request, requesting department and indication were obtained. The 2010 British Committee for Standards in Haematology (BCSH) clinical guidelines for testing for heritable thrombophilia was used as the standard for the audit.
Results: On 269 patients, 379 requests were made. Thirty-four per cent of tests were abnormal but only 36% of abnormal tests were repeated. Seven per cent of patients were confirmed with a heritable thrombophilia. Thirty-four tests were performed on patients on anticoagulation. The median age was 6.903 years. Fifty-three per cent of requests came from a ward, 28% from outpatients, 14% from an intensive care department and 5% from the emergency department. Departments most frequently requesting tests were neurology (20%), paediatric intensive care (15%) and cardiology (12%). Indications for testing were arterial thrombosis (5%), cerebral vein thrombosis (4%), deep vein thrombosis (12%), stroke (23%), asymptomatic relative (6%), intra-abdominal vein thrombosis (8%), start oestrogen containing medication (2%), purpura fulminans (0.2%), heparin resistance (8%) and other (35%).
Discussion: The large majority of requests did not satisfy the BCSH criteria. Requesting behaviours are haphazard. Better appreciation of the difficulties of interpreting results in children of different ages and in different clinical settings amongst paediatricians is required.